A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

January 16, 2013

Generic HIV Meds Could Save U.S. $1B a Year, But Risk Lowering Adherence

As first-line HIV medications begin to lose their patents, the U.S. health care system stands to save $1 billion a year, but a switch to generics may also raise the likelihood of treatment failure, MedPage Today reports. A study conducted by Massachusetts General Hospital and Weill Cornell Medical College and published in the January 15 Annals of Internal Medicine examines both the financial and health impacts of the release of generic antiretrovirals (ARVs).

Currently, the recommended therapy for treatment-naive people with HIV is the single-pill, once-a-day triple combination therapy Atripla, which is comprised of three brand-name ARVs: Viread (tenofovir), Emtriva (emtricitabine) and Sustiva (efavirenz). In January 2012, a generic form of the ARV lamivudine, which operates similarly to emtricitabine, was released. A generic of efavirenz is expected to hit the market soon.

The study indicates that adding the two generics to Viread to assemble a combination therapy comparable to Atripla would yield a lifetime savings of $42,500 for every eligible patient. Government sources, which pay for the lion’s share of HIV care in the United States, would benefit the most. However, because of the increased pill burden—there is no imminent promise of a once-a-day generic combo pill—people with HIV would likely be less adherent to the drug cocktail and run a greater risk of developing drug resistance. Furthermore, lab studies have suggested that lamivudine may be somewhat less effective than emtricitabine, as well as more likely to lead to the development of drug resistance.

To read the MedPage Today article, click here.

To read the Mass General Hospital and Weill Cornell Medical College release, click here.

To read the abstract of the study, click here.

Editor's Note: This article has been updated.

Search: HIV, antiretrovirals, ARV, medications, patent, savings, generic, MedPage Today, Massachusetts General Hospital, Weill Cornell Medical College, Atripla, Viread, tenofovir, Emtriva, emtricitabine, Sustiva, efavirenz, lamivudine


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (5 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    adoniz89
    san dimas
    California


    koffeeboss
    Tucson
    Arizona


    pevans
    San Francisco
    California


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.